Targeting calcium handling in A-fib

The drug ent-verticilide reduced A-fib incidence and duration in an animal model, suggesting it may be a viable therapeutic option.

Genes and age studied as markers for higher death rate in those with atrial fibrillation

Younger patients with atrial fibrillation who had rare genetic variants associated with inherited cardiomyopathy and arrythmia syndromes were associated with a significantly higher rate of death than those without the variants, a Vanderbilt-led study has shown.

Peptides promote AFib arrhythmia

Peptide oligomers have detrimental metabolic effects and cause pro-arrhythmic electrophysiological changes in heart atria, suggesting they may contribute to atrial fibrillation.

Study finds apixaban (Eliquis) is preferable to rivaroxaban (Xarelto) for stroke prevention, reduced bleeding complications

Study finds genetic testing useful for young AFib patients

Vanderbilt research shows that genetic testing in patients with early-onset atrial fibrillation can identify variants associated with more serious cardiomyopathy and arrhythmia syndromes that may otherwise remain undiagnosed.

VHVI offers latest therapies to treat atrial fibrillation

Vanderbilt Heart and Vascular Institute continues to offer the latest in therapies to treat atrial fibrillation (AF or AFib), the most common cardiac arrhythmia.